by Erin | Jun 17, 2025 | Blog
In recent years, prescription drug affordability boards (PDABs) have struggled as they implement their cost review and price-setting policies. Now, some states are attempting to cut out these regulatory processes entirely. Instead of creating new PDABs, some states...
by Erin | May 16, 2025 | Blog
The March meeting of the Maryland Prescription Drug Affordability Board (PDAB) ignited significant concerns among a broad group of patient, physician, pharmacist and caregiver organizations. Recent legislation requires the PDAB to conduct an analysis on the impact of...
by Erin | Apr 22, 2025 | Blog
An oft-repeated talking point for proponents of prescription drug affordability boards is that capping the top-line price of medications will result in lower premiums and out-of-pocket spending by patients. But a new report from the Partnership to Fight Chronic...
by Erin | Apr 9, 2025 | Blog
A new cost-benefit analysis from Colorado’s Department of Regulatory Agencies reveals a concerning finding: the government doesn’t know, and can’t predict, what the economic benefits of prescription drug affordability board policies might be. The analysis,...
by Erin | Mar 27, 2025 | Blog
The Value of Care Coalition previously asked: Who Do Prescription Drug Affordability Boards Actually Listen To? They don’t seem to be listening to the stakeholders providing comments or, in some cases, even their own analysts. Now, a new fact sheet from VCC examines...
